The Medecines Co. v. Mylan, Inc.

E-Law Admin/ April 6, 2017/ Arzneimittelrecht Schweiz/ 0Kommentare

The Medecines Co. v. Mylan, Inc., 2015-1113

In a suit filed in response to an Abbreviated New Drug Application (ANDA) submitted by defendant, involving patents directed to pharmaceutical formulations–or ‘batches’–of the drug bivalirudin, produced through a process that consistently minimizes impurities, the district court’s grant of summary judgment that the asserted claims of the ‘343 patent were not infringed because defendant did not satisfy the ‘efficient mixing’ limitation of those claims, and judgment that the asserted claims of the ‘727 patent were infringed because those claims did not include an ‘efficient mixing’ limitation, are: 1) reversed as to the district court’s judgment of infringement with respect to the ‘727 patent; and 2) affirmed as to summary judgment of noninfringement with respect to the ‘343 patent, where efficient mixing is required by the asserted claims of both patents.

Appellate Information

  • Argued
  • Submitted
  • Decided
  • Published 2017/04/06



  • United States Federal Circuit


e-Law Trainer

Share this Post

Hinterlasse einen Kommentar